Patent US4310546A successfully refreshed from Google Patents.
US4310546A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Novel retinoids and their use in preventing carcinogenesis
Assignee: Johnson and Johnson
•
Filing: 1978-07-31
•
Granted: 1982-01-12
•
Expires: 1998-07-31
Abstract
Abstract Novel N-(4-acyloxyphenyl)-all-trans-retinamide compounds are useful in preventing epithelial cancer in mammals.
Inventors
- 👤 Robert J. Gander
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 08:14
CPC Classifications
C; C07; C07C; C07C403/00; C07C403/20; C07B; C07B2200/00; C07B2200/09; C07C2601/00; C07C2601/12; C07C2601/16
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
15 words
An N-(4-acyloxyphenyl)-all-trans-retinamide having the structure: ##STR5## wherein n is an integer from 1 through 18.
Claim 2
Dependent Claim
15 words
An N-(4-acyloxyphenyl)-all-trans-retinamide having the structure: ##STR5## wherein n is an integer from 1 through 18.
Claim 3
Dependent Claim
17 words
An N-(4-acyloxyphenyl)-all-trans retinamide according to claim 1 selected from the group consisting of N-(4-acetoxyphenyl)-all-trans-retinamide, N-(4-propionyloxyphenyl)-all-trans-retinamide and N-(4-butyryloxyphenyl)-all-trans-retinamide.
Claim 4
Dependent Claim
5 words
N-(4-acetoxyphenyl)-all-trans-retinamide according to claim 1.
Claim 5
Dependent Claim
5 words
N-(4-propionyloxyphenyl)-all-trans-retinamide according to claim 1.
Claim 6
Dependent Claim
5 words
N-(4-butyryloxyphenyl)-all-trans-retinamide according to claim 1.
Claim 7
Dependent Claim
29 words
A composition for the treating carcinogenesis in epithelial tissue comprising an effective amount for treating carcinogenesis of a retinamide of claim 1 in a pharmaceutically acceptable vehicle compatible therewith.
Claim 8
Dependent Claim
11 words
The composition of claim 6 in which said retinamide is N-(4-acetoxyphenyl)-all-trans-retinamide.
Claim 9
Dependent Claim
11 words
The composition of claim 6 in which said retinamide is N-(4-propionyloxyphenyl)-all-trans-retinamide.
Claim 10
Dependent Claim
11 words
The composition of claim 6 in which said retinamide is N-(4-butyryloxyphenyl)-all-trans-retinamide.
Claim 11
Dependent Claim
9 words
The composition of claim 6 in oral dosage form.
Claim 12
Dependent Claim
36 words
A method of treating carcinogenesis in epithelial tissue in a mammal in need of said treatment, which comprises periodically administering to the subject mammal an effective amount for treating carcinogenesis of a retinamide of claim 1.
Claim 13
Dependent Claim
11 words
The method of claim 11 wherein said retinamide is administered orally.
Claim 14
Dependent Claim
14 words
The method of claim 12 wherein said retinamide is administered at least once daily.
Claim 15
Dependent Claim
18 words
The method of claim 11 wherein said retinamide is administered in an amount up to about 50 mg/kg/day.
Claim 16
Dependent Claim
10 words
The method of claim 11 wherein said retinamide is N-(4-acetoxyphenyl)-all-trans-retinamide.
Claim 17
Dependent Claim
10 words
The method of claim 11 wherein said retinamide is N-(4-propionyloxyphenyl)-all-trans-retinamide.
Claim 18
Dependent Claim
10 words
The method of claim 11 wherein said retinamide is N-(4-butyryloxyphenyl)-all-trans-retinamide.
References Cited (Backward Citations)
US4108880A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-01-11 | 1985-07-13 | 1986-01-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-01-11 | 1989-07-13 | 1990-01-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-01-11 | 1993-07-13 | 1994-01-12 | $7700.00 | Window Closed / Lapsed |